Akero Therapeutics, Inc. Marketable Securities (Current)
Akero Therapeutics, Inc. had Marketable Securities (Current) of $561.79 million as of 2025-09-30, per its 10-Q filed 2025-11-07.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:MarketableSecuritiesCurrent · last filed 2025-11-07
- 2025-09-30: Marketable Securities, Current $561.79M.
- 2025-06-30: Marketable Securities, Current $521.87M.
- 2025-03-31: Marketable Securities, Current $500.37M.
- 2024-12-31: Marketable Securities, Current $402.84M.
| Period end | Marketable Securities, Current |
|---|---|
| 2025-09-30 | $561.79M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $521.87M 10-Q · filed 2025-08-08 |
| 2025-03-31 | $500.37M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $402.84M 10-Q · filed 2025-11-07 |
| 2024-09-30 | $401.18M 10-Q · filed 2024-11-08 |
| 2024-06-30 | $449.84M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $279.81M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $315.80M 10-K · filed 2025-02-28 |
| 2023-09-30 | $285.19M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $195.29M 10-Q · filed 2023-08-11 |
| 2023-03-31 | $85.34M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $101.68M 10-K · filed 2024-02-29 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-04 |
| 2022-06-30 | $3.00M 10-Q · filed 2022-08-05 |
| 2022-03-31 | $14.89M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $37.77M 10-K · filed 2023-03-17 |
| 2021-09-30 | $50.15M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $72.49M 10-Q · filed 2021-08-13 |
| 2021-03-31 | $62.02M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $81.14M 10-K · filed 2022-02-25 |
| 2020-09-30 | $99.19M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $39.59M 10-Q · filed 2020-08-12 |
| 2020-03-31 | $78.04M 10-Q · filed 2020-05-13 |
| 2019-12-31 | $71.61M 10-K · filed 2021-03-16 |
| 2018-12-31 | $0.00 10-K · filed 2020-03-16 |